Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Clin Cancer Res. 2015 May 26;21(17):3995–4003. doi: 10.1158/1078-0432.CCR-14-2728

Figure 3. Effects of pharmacologic inhibition of Bcl2 and ER in ER+/HER2+ cells with acquired resistance to lapatinib in vitro.

Figure 3

A. Tumor cell growth relative to control (DMSO) evaluated by methylene blue assay after 6 days of treatment with DMSO, ABT-737 (1 μM), fulvestrant (Ful; 0.1 μM), or the combination of ABT-737 with Ful, in parental and lapatinib (L)-resistant UACC812 cells.

B. Evaluation of apoptosis by annexin V assay after 24 hours of treatment with either DMSO (control), ABT-737 (1 μM), Ful (0.1 μM), or the combination of ABT-737 with Ful, in parental and L-resistant UACC812 cells.

C. Western blot evaluation of phosphorylated (p)-HER2 and total (t)-HER2, and ER and its downstream gene products PR and Bcl2, in parental and L-resistant UACC812 cells after 72 hours of treatment with either DMSO, ABT-737 (1 μM), Ful (0.1 μM), or the combination of ABT-737 with Ful.